Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a bodywash, shampoo, conditioner, lotion, gel, soap, cream, hand sanitizer, spray or mousse and can be used by an individual during their normal hygiene processes, such as during a shower or bath or while applying a body product to their skin or hair.

Abstract: Provided are methods for inhibiting oxidation of unsaturated fats comprising blending the unsaturated fats with an effective amount of an antioxidant compound of Formula I: wherein R, R1, R2, R3, R4, R5 and R6 are as defined herein.

Abstract: Methods, kit and uses for treating hair are provided. A method for treating hair comprises applying to the hair a first composition comprising in a cosmetically acceptable carrier, one or more ionizable linkers of Formula I, or cosmetically acceptable salts thereof, or mixtures thereof: and applying to the hair a second composition comprising in a cosmetically acceptable carrier, one or more ingredients of Formula II, or cosmetically acceptable salts thereof, or mixtures thereof: and wherein the first composition does not comprise any ingredients of Formula II of the second composition. Alternatively, a method for treating hair comprises applying to the hair a composition comprising in a cosmetically acceptable carrier, one or more ionizable linkers of Formula I, or cosmetically acceptable salts thereof, or mixtures thereof; and one or more ingredients of Formula II, or cosmetically acceptable salts thereof, or mixtures thereof.

Abstract: Disclosed are compositions for treating and conditioning keratinous substrates, comprising a first cationic surfactant chosen from alkyl quaternary ammonium or diammonium salts; a second cationic surfactant chosen from alkyl amines or alkyl amine salts; a first silane compound, a cationic vinylpyrrolidone polymer, fatty alcohols, glyceryl esters, organic acids, and water. Also disclosed are methods treating and conditioning keratinous substrates using the composition.

Abstract: This document relates to materials and methods for topical administration of sulfonylureas to inhibit, reduce, or prevent hair growth the topical composition being formulated for application to the skin of a mammal. The materials and methods of the disclosure may be used to inhibit, reduce, or prevent any unwanted hair growth including normal growth, and excessive hair growth.

Abstract: The present disclosure relates to a multi-phase liquid agent for the non-chemical smoothing and de-curling of keratin fibers, in particular human hair, which has an aqueous-alcoholic phase and a non-aqueous phase existing separately therefrom and which can be applied as a spray, and a method for non-chemical smoothing or de-curling of keratin fibers using the agent.

Abstract: The invention relates to nail compositions including water, at least one water-soluble organic coloring agent and at least one film forming agent containing styrene, wherein the film forming agent minimizes staining of a nail by the water-soluble organic coloring agent to which the composition has been applied.

Abstract: The disclosure relates to a cosmetic composition for the temporary shaping of hair, containing a combination of two specific anionic acrylate copolymers. The cosmetic composition provides an extremely good moisture resistance.

Abstract: The invention relates to a cosmetic composition for the temporary shaping of hair, comprising a combination of two specific anionic acrylate copolymers. The cosmetic composition provides an extremely good moisture resistance.

Abstract: The disclosure relates to a cosmetic composition for the temporary shaping of hair, containing a combination of two specific anionic acrylate copolymers. The cosmetic composition provides an extremely good moisture resistance.

Abstract: The disclosure relates to a cosmetic composition for the temporary shaping of hair, containing a combination of an anionic acrylate polymer and an amphoteric polymer. The cosmetic composition provides an extremely good moisture resistance.

Abstract: The disclosure relates to a cosmetic composition for the temporary shaping of hair, containing a combination of two specific copolymers, a polymeric quaternary ammonium compound from the group of the vinylpyrrolidone copolymers and an anionic acrylate copolymer. The cosmetic composition provides an extremely good moisture resistance.

Abstract: A self-tanning composition for application to wetted skin after showering, and the like, which provides moisturizing and skin coloration, all over body spreadability, and easy application. The self-tanning composition comprises: a quaternary ammonium salt; a reducing sugar; and at least one silicone.

Abstract: Provided is a topical apple product, comprising a base topical product configured for application to a human and an apple material substantially uniformly combined with the base topical material. Also provided is a method of treating a skin condition or ailment with topical apple product. The apple material can have a Polyphenols/Total Antioxidant Activity of ?3.00%.

Abstract: A cosmetic composition for whitening skin and a preparation method thereof The composition comprises the following components: pearl powder, pearl extract, glycyrrhiza glabra aqueous solution, hydrolyzed conchiolin protein and pea extract. The contents of the pearl powder and the pearl extract are not both zero, and the glycyrrhiza glabra aqueous solution contains 0.5 to 5.0% of the glycyrrhiza glabra extract.

Abstract: The present invention relates to a polymer solution for use as a rheological blood substitute. The rheological blood replacement solution comprises in its basic composition a water-soluble cellulose polymer with a molecular weight of 100 kDa or greater, polyethylene oxide and a solvent. The rheological blood replacement solution of the invention can be used in a variety of applications, e.g. as blood substitute, calibration agent or reference agent. The blood replacement solution is based on a polymer solution, which can also be used as pharmaceutical composition, e.g. for the prevention or treatment of haemorrhage or shock-related disorders.

Abstract: The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, and uses thereof.

Abstract: A minimally invasive controlled drug delivery system for delivering a particular drug or drugs to a particular location of the eye, the system including a porous film template having pores configured and dimensioned to at least partially receive at least one drug therein, and wherein the template is dimensioned to be delivered into or onto the eye.

Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.

Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Abstract: The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small molecules to target cells in vitro and in vivo, and methods for such ARMM-mediated delivery are provided herein. Diagnostic and therapeutic methods using ARMMs are also described herein.

Abstract: An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned.

Abstract: The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a phosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, and one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: A method for making composite excipient particles for use in a pharmaceutical composition comprises a milling step in which particles of an excipient material are milled in the presence of an additive material. The product particles are of small size and the milling requires relatively low input of time and energy. The composite particles are suitable for use in inhalable pharmaceutical compositions.

Abstract: A method for making a controlled release material, comprising the steps of: — (a) forming granules comprising one or more wax and one or more disintegrant; (b) spheronisation of the granules and (c) compaction of the spheronised granules of step so as to form the controlled release material. The invention also relates to a tablet and delayed and sustained release material made according to the method.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Abstract: Pharmaceutical blends are disclosed herein. In some embodiments, a pharmaceutical blend includes a cohesive active pharmaceutical ingredient (API) and a dry coated pharmaceutical excipient. The dry coated pharmaceutical excipient is present in an amount of about 1 wt % to 99 wt %, based on the total weight of the pharmaceutical blend. The dry coated pharmaceutical excipient includes a core and a shell surrounding the core, wherein the shell partially covers the core of the pharmaceutical excipient.

Abstract: A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form and at least one liquid fill phase. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. Method and apparatus for manufacturing the multi phase soft gelatin dosage forms are also described. The solid phase, liquid phase or coatings may comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, therapeutic substances, functional excipients or combinations thereof.

Abstract: A composition includes a hydrogel bead in an external matrix, the hydrogel bead having an at least partially crosslinked gelling polymer, the hydrogel bead having encapsulated therein a functional agent, and a buffering agent having low water solubility, wherein at least a portion of the buffering agent is in solid form in the hydrogel bead.

Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).

Abstract: Methods for the formulation of biodegradable microparticles for delivery of protein drugs, such as botulinum toxin, have been developed. The methods include the steps of precipitating and washing proteins with organic solvent to remove water prior to dispersing in polymer-dissolved organic solvent to prevent exposure to water/solvent interfaces and maintain bioactivity of the protein drugs and fabrication of microparticles by either template or emulsion method. Biodegradable microparticles, formed of one or more biodegradable polymers having entrapped in the polymer one or more protein agents, such as botulinum toxin, are also provided. Precipitated botulinum toxin and botulinum toxin-loaded microparticles can also be formulated into thermogels or crosslinked hydrogels. The stability of the protein within these microparticles, as well as the controlled release of the entrapped agents, provides for sustained efficacy of the agents.

Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

Abstract: Provided herein are therapeutic nanoparticles having a diameter of between 10 nm to 30 nm, and containing a polymer coating, and a nucleic acid containing a sequence complementary to a sequence within a micro-RNA identified as having a role in cancer cell metastasis or anti-apoptotic activity in a cancer cell (e.g., miR-10b) or a sequence within an mRNA encoding a pro-apoptotic protein that is covalently linked to the nanoparticle. Also provided are pharmaceutical compositions containing these therapeutic nanoparticles. Also provided herein are methods of decreasing cancer cell invasion or metastasis in a subject having a cancer and methods of treating a metastatic cancer in a lymph node in a subject that require the administration of these therapeutic nanoparticles to a subject.

Abstract: Novel process and products thereby emplace NSAIDS within nanodelivery vehicles for various indications in mammals, including humans.

Abstract: The present invention provides a patch comprising a backing and an adhesive agent layer laminated on the backing, wherein the adhesive agent layer comprises ropinirole or a pharmaceutically acceptable salt thereof, an organic amine or an acid addition salt thereof, and an adhesive agent.

Abstract: A transdermal dosing unit may include a first segment having a first pharmaceutical in a first reservoir, a first releasing compound, and a first adhesive component, a second segment removably connected to the first segment, the second segment having a second pharmaceutical in a second reservoir, a second releasing component, and a second adhesive component, and a backing component. The transdermal dosing unit may further include additional segments, and may include a perforated section between each segment. The first adhesive component may have a first adhesion strength, and the second adhesive component may have a second adhesion strength that is either different from or approximately equal to the first adhesion strength. A method of titrating a dose of such a transdermal dosing unit may include applying the transdermal dosing unit to a subject, and removing the first segment while leaving the second segment on the subject.

Abstract: Provided are methods and devices useful for treating a respiratory disease or disorder involving the central or upper airways. The methods and devices deliver to central or upper airways of a subject a vapor or aerosol comprising an effective amount of an active ingredient selected from the group consisting of menthol, menthone, neomenthol, isomenthol, and menthofuran. The methods are useful for treating conditions including cough, asthma, bronchitis, and allergic rhinitis.

Abstract: Disclosed is a method of treating or ameliorating a condition which can be treated or ameliorated by the administration of guaifenesin, which method comprises orally administering to a subject in need thereof an effective amount of an an immediate release solution for oral administration of guaifenesin and at least one additional drug. In addition to water the solution comprises as solvents propylene glycol and glycerol in a concentration which significantly increases the bioavailability of guaifenesin in the human body.

Abstract: A Curcumin infused milk beverage composition comprising 0.05% to 0.15% alkalized Curcumin, standardized milk with fat, sugar and stabilizing agents, wherein the pH of resultant composition is maintained at 6.8.

Abstract: The present invention relates to astaxanthin compositions for use in foodstuffs, food supplements or feedstuffs or as a medicament. Astaxanthin compositions which comprise at least 50% by weight, in particular at least 60% by weight, especially preferably at least 70% by weight and specifically at least 80% by weight or at least 90% by weight, based on the total weight of astaxanthin and astaxanthin derivatives in the composition, of an astaxanthin monoester with a C18-1 fatty acid have a particularly good bioavailability. They are therefore particularly suitable for use in foodstuffs, food supplements or feedstuffs and for the therapeutic use as medicament and as constituent for medicinal preparations and pharmaceutical compositions.

Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.

Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.

Abstract: Activation of 5-HT2A receptors using agonists at surprisingly low concentrations was shown to potently inhibit TNF-?-induced inflammation in multiple cell types. Significantly, proinflammatory markers were also inhibited by the agonist, (R)-DOI, even many hours after treatment with TNF-?. With the exception of a few natural toxins, no current drugs or small molecule therapeutics demonstrate a comparable potency for any physiological effect. TNF-? and TNF-? receptor mediated inflammatory pathways have been strongly implicated in a number of diseases, including atherosclerosis, asthma, rheumatoid arthritis, psoriasis, type II diabetes, depression, schizophrenia, and Alzheimer's disease. Importantly, because (R)-DOI can significantly inhibit the effects of TNF-? many hours after the administration of TNF-?, potential therapies could be aimed not only at preventing inflammation, but also treating inflammatory injury that has already occurred or is ongoing.

Abstract: Provided herein are polymers comprising Metformin residues (“PolyMet”) as useful therapeutic agents, delivery vehicles and transfection agents for nucleotides. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering PolyMet as a therapeutic agent to combat the disease or condition. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering a therapeutic agent in a delivery vehicle that comprises PolyMet. Further provided herein are methods for making PolyMet.

Abstract: The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.

Abstract: The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.

Abstract: The present technology provides siderophore-polymer conjugates that enhance the sensitivity of bacteria to antibiotics, e.g., Pseudomonas, P. aeruginosa, Acinetobacter, and A. baumannii.Methods of preparing and using such conjugates to treat bacterial infections are disclosed.

Abstract: A pharmaceutical composition exhibiting anti-tumor activity is provided. The pharmaceutical composition comprises para-toluenesulfonamide (PTS) and a pharmaceutically acceptable carrier. The pharmaceutical composition is used for treating squamous-cell carcinoma. The present invention further provides a method for treating a patient suffering from cancer and a method for inhibiting tumor growth.

Abstract: A foodstuff can include sodium D-?-hydroxybutyrate, potassium D-?-hydroxybutyrate, and/or calcium D-?-hydroxybutyrate.